Login
Emergent BioSolutions Inc NYSE: EBS
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
| Name | Emergent BioSolutions Inc |
| Ticker | EBS |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
|
Price
52W Low/High |
74.47
62.58 / 134.94 |
| Momentum | Sharp Down |
| Market cap | 3.9 B |
| 1Y Total Return |
19.00%
Weak |
| 1Y Volatility |
61.30%
High Risk |
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Details
| Ticker | EBS |
| Name | Emergent BioSolutions Inc |
| ISIN | US29089Q1058 |
| CUSIP | 29089Q105 |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 4/14/21
| Close Price | 74.47 |
| 52W Low/High | 62.58 / 134.94 |
| Market cap | 3.9 B |
| 1Y Total Return |
19.00%
Weak |
| 1Y Volatility |
61.30%
High Risk |
| Beta | 1.09 |
| PE (trailing) |
13.13
Low |
| 12M Dividends | - |
| Last Dividend Date | 8/1/16 |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 19.6% |
| Cash from Op. / Cur. Liabilities | 1.39 |
| Diluted Earnings / Share | 5.67 |
| ROE | 24.1% |
| ROIC | -7.3% |
| Price / Revenue | 2.6 |
| Price / Book | 2.8 |
| Price / CF | 7.5 |
| Current Ratio | 3.1 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 0.60 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
1,555
|
1,106
|
782
|
561
|
489
|
489
|
|
| Gross Profit |
1,031
|
673
|
460
|
373
|
363
|
382
|
|
| R&D |
235
|
226
|
143
|
97
|
107
|
119
|
|
| EBITDA |
553
|
227
|
154
|
168
|
134
|
149
|
|
| Operating Income |
434
|
114
|
90
|
124
|
106
|
142
|
|
| Net Income exc. Extra |
305
|
55
|
63
|
83
|
52
|
63
|
|
| per Share | |||||||
| Diluted avg Shares |
54
|
52
|
51
|
50
|
49
|
47
|
|
| EPS exc. Extra |
5.67
|
1.04
|
1.22
|
1.71
|
1.13
|
1.41
|
|
| Dividend |
-
|
-
|
-
|
-
|
2.00
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
6.09%
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
2,883
|
2,327
|
2,229
|
1,070
|
970
|
1,037
|
|
| Cash, Eq & Invt ShortTerm |
622
|
168
|
112
|
179
|
272
|
308
|
|
| Total Current Assets |
1,196
|
686
|
621
|
485
|
510
|
537
|
|
| Total Non-Current Assets |
1,687
|
1,641
|
1,609
|
585
|
460
|
500
|
|
| Intangibles |
930
|
980
|
1,021
|
169
|
75
|
82
|
|
| Total Liabilities |
1,436
|
1,239
|
1,219
|
158
|
374
|
377
|
|
| Total Current Liabilities |
385
|
216
|
200
|
100
|
106
|
100
|
|
| Long Term Debt |
1,052
|
1,023
|
1,018
|
58
|
268
|
278
|
|
| Shareholder equity |
1,447
|
1,089
|
1,011
|
912
|
596
|
660
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
536
|
188
|
42
|
208
|
55
|
43
|
|
| Depreciation |
115
|
111
|
62
|
43
|
38
|
35
|
|
| Cash from Investing |
-151
|
-97
|
-897
|
-250
|
-76
|
-45
|
|
| Capex |
141
|
87
|
72
|
55
|
76
|
45
|
|
| Cash from Financing |
70
|
-36
|
789
|
-51
|
-20
|
35
|
|
| Stock Issued |
32
|
8
|
16
|
-14
|
17
|
26
|
|
| Debt (LT) Issued |
55
|
14
|
782
|
-21
|
0
|
2
|
|
| Free Cash Flow |
-186
|
42
|
-15
|
-32
|
-6
|
-32
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
19.6%
|
4.9%
|
8.0%
|
14.7%
|
10.6%
|
12.8%
|
|
| NCFO / Op.Income |
123.6%
|
164.8%
|
46.5%
|
167.4%
|
51.8%
|
30.0%
|
|
| Current Ratio |
3.1
|
3.2
|
3.1
|
4.8
|
4.8
|
5.4
|
|
| Financial Leverage D/E |
0.60
|
0.75
|
0.79
|
0.01
|
0.45
|
0.37
|
|
| Return on Capital Avg |
-7.3%
|
4.3%
|
5.7%
|
10.7%
|
10.3%
|
6.4%
|
|
| Return on Shareholder Equity |
24.1%
|
5.2%
|
6.5%
|
11.0%
|
8.2%
|
10.4%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available